Onconetix Stock Today
| ONCO Stock | USD 4.12 0.09 2.23% |
PerformanceVery Weak
| Odds Of DistressVery High
|
Onconetix is selling at 4.12 as of the 26th of June 2025; that is 2.23 percent increase since the beginning of the trading day. The stock's open price was 4.03. Onconetix has a very high chance of experiencing financial distress in the next few years of operation. It has also generated negative returns for investors over the last 90 days. The performance scores are derived for the period starting the 28th of March 2025 and ending today, the 26th of June 2025. Click here to learn more.
Oncology Med, Inc. offer full service cancer center solutions. The company has 521.86 K outstanding shares of which 1.84 M shares are now shorted by private and institutional investors with about 0.04 trading days to cover. More on Onconetix
Follow Valuation Odds of Bankruptcy
Check how we calculate scores
Onconetix Stock Highlights
| Executive Chairman | RPh MBA |
| Business Concentration | Pharmaceutical Products, Biotechnology, Healthcare, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) |
Onconetix (ONCO) is traded on NASDAQ Exchange in USA. It is located in 201 East Fifth Street, Cincinnati, OH, United States, 45202 and employs 5 people. Onconetix is listed under Pharmaceutical Products category by Fama And French industry classification. The company currently falls under 'Nano-Cap' category with a current market capitalization of 2.23 M. Onconetix conducts business under Biotechnology sector and is part of Health Care industry. The entity has 521.86 K outstanding shares of which 1.84 M shares are now shorted by private and institutional investors with about 0.04 trading days to cover.
Onconetix currently holds about 113.36 K in cash with (10.5 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.85.
Check Onconetix Probability Of Bankruptcy
Ownership AllocationOnconetix holds 11.68 pct. of its outstanding shares held by insiders and 0.81 pct. owned by third-party entities.
Check Onconetix Ownership Details
Onconetix Risk Profiles
Investors will always prefer to have the highest possible return on investment while minimizing volatility. Onconetix market risk premium is the additional return an investor will receive from holding Onconetix long position in a well-diversified portfolio.
| Risk Adjusted Performance | (0.12) | |||
| Jensen Alpha | (0.72) | |||
| Total Risk Alpha | (0.89) | |||
| Treynor Ratio | (0.79) |
Onconetix Stock Against Markets
Onconetix Corporate Management
| Theodore Yoho | Head Development | Profile | |
| MBA MA | Senior Development | Profile | |
| Andrew Skibo | Global Operations | Profile | |
| MD MBA | Chief Officer | Profile | |
| Christian Bruhlmann | Chief Officer | Profile | |
| Dr Very | Senior Development | Profile | |
| Erin Henderson | Consultant | Profile |
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Onconetix. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. To learn how to invest in Onconetix Stock, please use our How to Invest in Onconetix guide.You can also try the Odds Of Bankruptcy module to get analysis of equity chance of financial distress in the next 2 years.
Is Pharmaceutical Products space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Onconetix. If investors know Onconetix will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Onconetix listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Onconetix is measured differently than its book value, which is the value of Onconetix that is recorded on the company's balance sheet. Investors also form their own opinion of Onconetix's value that differs from its market value or its book value, called intrinsic value, which is Onconetix's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Onconetix's market value can be influenced by many factors that don't directly affect Onconetix's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Onconetix's value and its price as these two are different measures arrived at by different means. Investors typically determine if Onconetix is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Onconetix's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.